Approaches to help people with diabetes overcome barriers for improved health outcomes

Diabetes Educator

Volumn 34, Issue 1, 2008, Pages

  Siminerio, Linda M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ARTICLE; ATTITUDE TO HEALTH; DIABETES MELLITUS; FEAR; HEALTH CARE DELIVERY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGICAL ASPECT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ATTITUDE TO HEALTH; DELIVERY OF HEALTH CARE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEAR; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; TREATMENT OUTCOME;

EID: 38949201766     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721707313938     Document Type: Article

References (30)

1. American Association of Clinical Endocrinologists. State of diabetes in America. http://www.aace.com/public/awareness/stateofdiabetes/ DiabetesAmericaReport.pdf. Accessed September 5, 2007.
2. Koro CE, Bowlin SJ, Bourgeois N., Fedder DO Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004 ; 27: 17-20.
3. Shah BR, Hux JE, Laupacis A., Zinman B., van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians ? Diabetes Care. 2005 ; 28: 600-606.
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002 ; 26 (suppl 3). S18 - S24.
5. Heinemann L. Overcoming obstacles: new management options. Eur J Endocrinol. 2004 ; 151: T23 - T27.
6. Fertig BJ, Simmons DA, Martin DB Therapy for diabetes. In: Harris MI, et al. Diabetes in America. 2 nd ed. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases ; 2005.
7. Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005 ; 118 (suppl 5A). 27S - 34S.
8. Siminerio L. Challenges and strategies for moving patients to injectable medications. Diabetes Educ. 2006 ; 32 (suppl 2). 82S - 90S.
9. Edelman S., Garg S., Frias J., et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006 ; 29: 2189-2195.
10. Hollander PA, Levy P., Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care. 2003 ; 26: 784-790.
11. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2005.
12. Karl D., Philis-Tsimikas A., Darsow T., et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007 ; 9: 191-199.
13. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc ; 2007.
14. Buse JB, Henry RR, Han J., Kim DD, Fineman MS, Baron AD; for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2628-2635.
15. DeFronzo RA, Ratner RE, Han J., Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 1092-1100.
16. Ratner RE, Maggs D., Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006 ; 8: 419-428.
17. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc ; 2007.
18. Idris I., Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug [review]. Diabetes Obes Metab. 2007 ; 9: 153-165.
19. Charbonnel B., Karasik A., Liu J., Wu M, Meininger G; for the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006 ; 29: 2638-2643.
20. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006 ; 32: 9S - 18S.
21. Siminerio L., Zgibor J., Solano FX Jr. Implementing the chronic care model for improvements in diabetes practice and outcomes in primary care: the University of Pittsburgh Medical Center experience. Clin Diabetes. 2004 ; 22: 54-58.
22. Mollema ED, Snoek FJ, Adr HJ, Heine RJ, van der Ploeg HM Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 2001 ; 51: 665-672.
23. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med. 2001 ; 18: 671-674.
24. Martinez L., Consoli SM, Monnier L., et al. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring, and initial validation of a new self-administered questionnaire. Health Quality Life Outcomes. 2007 ; 5. http://www.hqlo.com/content/5/1/53. Accessed September 5, 2007.
25. Siminerio LM, Piatt GA, Emerson S., et al. Deploying the chronic care model to implement and sustain diabetes self-management training programs. Diabetes Educ. 2006 ; 32: 253-260.
26. Want L. Optimizing treatment success with amylin analogues. Presented at: Satellite Symposium of 34th Annual American Association of Diabetes Educators Conference ; August 2, 2007 ; St. Louis, MO.
27. Edelman S. Optimizing diabetes treatment utilizing an amylin analogue. Presented at: Satellite Symposium of the 34th Annual American Association of Diabetes Educators Conference ; August 2, 2007 ; St. Louis, MO.
28. Centers for Disease Control and Prevention. Guiding Principles for Diabetes Care: For Health Care Providers. NIH publication 99-4343. 2004. http://www.ndep.nih.gov/diabetes/pubs/GuidPrin_HC_Eng.pdf. Accessed September 4, 2007.
29. Centers for Disease Control and Prevention. Comprehensive Lifetime Management for Diabetes. NDEP-36. 2001. http://www.ndep.nih.gov/diabetes/pubs/ TeamCare.pdf. Accessed September 4, 2007.
30. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007 ; 30 (suppl 1). S4 - S41.